| __timestamp | Iovance Biotherapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 59644696 |
| Thursday, January 1, 2015 | 12390000 | 79541000 |
| Friday, January 1, 2016 | 25602000 | 98015000 |
| Sunday, January 1, 2017 | 21262000 | 103958000 |
| Monday, January 1, 2018 | 28430000 | 103654000 |
| Tuesday, January 1, 2019 | 40849000 | 128951000 |
| Wednesday, January 1, 2020 | 60210000 | 135799000 |
| Friday, January 1, 2021 | 83664000 | 149883000 |
| Saturday, January 1, 2022 | 104097000 | 220206000 |
| Sunday, January 1, 2023 | 106916000 | 265542000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Iovance Biotherapeutics, Inc. and Travere Therapeutics, Inc. have shown contrasting trends in their SG&A expenses from 2014 to 2023. Iovance's SG&A costs have increased by over 1,000% during this period, starting from approximately $9 million in 2014 to over $106 million in 2023. Meanwhile, Travere's expenses have surged by around 345%, from nearly $60 million to $266 million.
While both companies have seen significant increases, Travere's expenses have consistently been higher, peaking in 2023. This could indicate a more aggressive expansion strategy or higher operational costs. Understanding these trends can provide investors with insights into each company's financial strategies and operational efficiencies.
Breaking Down SG&A Expenses: AstraZeneca PLC vs Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.